Table 2.
Pretrial characteristics1 of the subjects in placebo and stanol groups.
| Placebo group (N = 34) |
Stanol group (N = 36) |
|
|---|---|---|
| Gender (male /female) (n) | 12/22 | 14/22 |
| Ethnicity | ||
| Caucasian (n) | 34 | 36 |
| Age (years) | 58.3 ± 7.9 | 59.1 ± 7.7 |
| Weight (kg) at | ||
| Screening | 74.4 ± 14.9 | 75.9 ± 15.8 |
| Baseline | 74.5 ± 15.0 | 75.8 ± 15.6 |
| 4 weeks | 74.5 ± 15.0 | 76.0 ± 15.8 |
| Height (cm) at Screening | 166.7 ± 9.6 | 168.5 ± 9.3 |
| Body mass index (kg/m2) | ||
| Screening | 26.7 ± 4.5 | 26.6 ± 4.9 |
| Baseline | 26.8 ± 4.6 | 26.6 ± 4.8 |
| 4 weeks | 26.7 ± 4.5 | 26.7 ± 4.9 |
| Serum glucose (mmol/l) | 5.0 ± 0.4 | 5.2 ± 0.5 |
| S-Thyroid stimulating hormone (mU/l) | 2.2 ± 1.2 | 2.1 ± 1.1 |
| S-Creatinine (μmol/l) | 67.2 ± 14.5 | 71.5 ± 12.8 |
1Values are means ± SD for continuous variables. There were no statistically significant differences in the baseline characteristics between the groups.